Dr. Anthony Brown

Anthony Brown is Research Director of BerGenBio, Bergen, Norway & Oxford, UK and honorary lecturer at Keele University School of Pharmacy.. In 1993 he obtianed PhD at Labolatory of Molecular Biophysics, Oxford University, UK. He completed with distinction his executive MBA at Oxford Brookes University, UK.

Dr Anthony Brown has extensive experience (25 years) in both small molecule and biological drug discovery with a focus in Oncology, R&D, technology transfer and commercialisation and buisness development. Dr Brown was Scientific Director in CellCentric, Cambridge,UK, Assosiate Director of Buisness Management, CRT, London, UK, Director of Biology, Piramed Pharma, Slough, UK, Director of Discovery Sciences, Surface Therapeutics, Abingdon, UK, Senior Group Leades, OSI Pharateceuticals, Oxford, UK and Group Leader/Consultant Scientist, British Biotech Ltd., Oxford, UK.  From 2008 he is founder and owner of Drug Discovery Ltd. and from 2011 Independent consultant to UK Biotechs




Prof. James Lorens

Professor James Lorens is a Professor at the Department of Biomedicine at the University of Bergen and the co-founder of BerGenBio, where he serves as the company’s Chief Scientific Officer. On completing his postdoctoral research studies at Stanford University he joined Rigel Inc., a San Francisco based biotechnology company, as a founding scientist and research director. Prof Lorens has managed several large scientific collaborations in cancer research and development with major pharmaceutical and biotechnology companies.  researchers. His group is active in EMT, angiogenesis and cancer research. Prof. Lorens is an author of more than 70 peer-reviewed articles and patents.





Prof. Richard Clarckson

Richard Clarkson is Senior Lecturer of cancer research at Cardiff University School of Biosciences and is a Principal Investigator in the European Cancer Stem Cell Research Institute.  He is also co-founder of the UK based Biopharmaceutical company, Tiziana Life Science Plc. Dr Clarkson received his PhD from the Faculty of Medicine, University of Manchester . His research group focuses on applying this knowledge to identify novel therapeutic strategies to eliminate or modify the tumour stem cells responsible for the spread of metastatic tumours around the body. This has culminated in the identification of two novel pharmacological agents that are currently undergoing pre-clinical development. These agents were licenced to Tiziana Life Sciences Plc, an AIM listed company co-founded by Dr Clarkson and colleagues, which has a portfolio of clinical and pre-clinical therapeutics focusing on cancer and immune modulation





Dr. Luca Cassetta

Dr. Luca Cassetta obtained his PhD at the University of Milan in the field of HIV immunology. In 2011 he joined Jeffrey Pollard`s lab moving to the Albert Einstein College of Medicine in NY working in the field of tumor immunology with a special focus on human tumor associated macrophages in breast cancer.. In 2013 Dr Cassetta moved together with Jeff Pollard to UK, where he still works at the University of Edinburgh. Dr Cassetta is interested in the role of WNT signalling pathway in breast cancer metastasis.. Dr. Cassetta is a Group Leader together with Prof. Gose Adema at the COST Action focusing at Myeloid Regulatory Cells. He is also a president of Airinforma, the project by International Association of Italian Researchers that has recently started a novel scientific dissemination initiative to the general public. Scientists involved in this project use their scientific expertise to gather and publish scientific news and concepts, explained using simple yet accurate language.




Prof. Gosse J. Adema

Gosse Adema is Chair in Molecular Immunology, Radiotherapy & OncoImmunology laboratory, Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Centre (Radboud UMC). He  obtained  his PhD degree in 1991 from the University of Utrecht, working at the department of Physiological Chemistry. He held a post-doc position at the division of Immunology at the Netherlands Cancer Institute (1991-1994) where he discovered the melanocyte differentiation antigen Gp100, and uncovered its recognition by the immune system. In 1994 he moved to the Radboud UMC to start his own research group at the department of Tumor Immunology. Since 2003 he became full professor and holds the chair in Molecular Immunology at the department of Tumor Immunology and from 2017 in Radiotheraphy & OncoImmunology laboratory, Department of Radiation Oncology. In the same year he became theme leader of the NCMLS theme on Infection, Immunity and Tissue Regeneration (150 scientists). Gosse Adema received the Eijkman Winkler Medal of the University of Utrecht (2004), the VICI award from the Netherlands organization for Scientific Research (2006), the CRI – CLIP award (2012) and the Radboud University Educational Price (2011) for his work in the International Master program Molecular Mechanisms of Disease. He has written > 10 patents and supervised >20 Ph.D. students. Since 2008 he is a member of the board of the Scientific Council of the Dutch Cancer Society. Furthermore, he is a member of the FWO (2009) expert panel for Microbiology and Immunology and of the French Cancer Institute (2009).


Prof. Michele de Palma

Michele De Palma  obtained in 2004 a PhD Degree in Cell Biotechnologies from the University of Torino Medical School, where he studied the contribution of bone marrow-derived cells to tumor angiogenesis under the direction of gene therapy pioneer, Dr. Luigi Naldini. He obtained Fellowship for 2004-2006 from Italian Association for Cancer Research (AIRC), Young Investigator Award from European Society of Gene Therapy (ESGT) in 2007. He performed his post-doctoral training at the Telethon Institute for Gene Therapy (TIGET) in Milan, where he further characterized the proangiogenic functions of tumor-associated macrophages and developed gene transfer strategies for reprogramming them into antitumoral effector cells. He serves on the editorial/advisory boards of Science Translational Medicine (AAAS), Cell Reports (Cell press), BBA-Reviews on Cancer, Cancer Immunology Research (AACR), and Carcinogenesis. In 2008 he was appointed group leader at the San Raffaele Scientific Institute, Milan. In 2009 he got Starting Grant from European Research Council (ERC). Michele joined the Swiss Institute for Experimental Cancer Research, at the EPFL School of Life Sciences in 2012. The same year he got Anna Fuller Prize, a year later Leenaards Prize and in 2013 he recieved AAAS Wachtel Cancer Research Award (Honorable Mention).



Prof. Jo van Ginderachter

Jo van Ginderachter is a Group Leader at VIB Lab of Myeloid Cell Immunity since October 2012. He joined Free University of Brussels in 1990 as a PhD student.. Over the years, his cellular immunology group has developed several experimental model systems that allow a detailed study of the mechanisms governing immune modulation in both normal and pathological conditions. More recently, the field of innate immunity, in particular the immunobiology of myeloid cells (MCs), became a central research topic. His strategic vision is to use the heterogeneity of MCs (mainly monocytes, macrophages and dendritic cells) as an in vivo sensor to track inflammatory responses and as a target for therapeutic intervention. He also exploits the strategic advantage of Nanobodies as tools for in vivo imaging and therapeutic targeting of MCs.





Prof. Cezary Szczylik

Cezary Szczylik is Head of Department of Oncology Military Institute of Medicine and Laboratory of Molecular Oncology, WIM, Poland. He obtained his PhD in 1978 at Military Institute of Medicine. In 1984 he has performed the first allogenic bone marrow transplant in Poland, and a year later the first autogenic bone marrow transplant (both together with Prof W. Jedrzejczak). In 1988 he obtained his postdoctoral degree (Dr hab.) and a year later he has been awarded by the fellowship at Thomas Jefferson University in Philadelphia (US).. Prof Szczylik received many awards, e.g.: 1st Scientific Team Prize of the Military Institute of Medicine, “Cristal mirror”, 1st Scientific Prize of the Military Institute of Medicine, “Puls of Medicine” distinction for the most prominent personality in polish medicine. He was Editor-in-chief in “Lancet Oncology”.





Prof. Ali O. Gure

Ali O. Gure is an Associate Professor at Bilkent University, Department of Molecular Biology and Genetics, Ankara, Turkey. Obtained his PhD in immunology from Cornell University Graduate School of Medical Sciences, USA, in 1995. Worked as Visiting Assistant Professor of Immunology at Weill Medical College of Cornell University (2006-2012), as an Assistant Member at the Ludwig Institute for Cancer Research - NYC branch (2000-2006) and as Research Associate at Memorial Slotan Kettering Cancer Center (2000-2006) after completing a post-doctoral fellowship with Lloyd J. Old at the Memorial Sloan Kettering Cancer Center in New York City (1995-2000). His initial work focused on the discovery of tumor antigens and in particular the utilization of autologous immune responses against these as diagnostic and prognostic markers. He is thus, a co-inventor of more than 25 international patents related to tumor antigens/biomarkers. His more recent work focuses on those mechanisms leading to expression of cancer-testis antigen genes which function as biomarkers of ectopic hypomethylation in cancer, and the identification of biomarkers of diagnosis, prognosis and chemosensitivity.